33.29
1.16%
-0.39
Handel nachbörslich:
32.70
-0.59
-1.77%
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
First Week of August 2025 Options Trading For Exelixis (EXEL) - Nasdaq
Exelixis downgraded to market perform by BMO Capital - MSN
The five-year decline in earnings might be taking its toll on Exelixis (NASDAQ:EXEL) shareholders as stock falls 4.3% over the past week - Simply Wall St
Exelixis (NASDAQ:EXEL) Stock Rating Lowered by BMO Capital Markets - MarketBeat
Franklin Resources Inc. Has $20.85 Million Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam - Yahoo Finance
Exelixis downgraded, price target raised to $40 on CRC drug outlook By Investing.com - Investing.com South Africa
Exelixis downgraded, price target raised to $40 on CRC drug outlook - Investing.com Canada
Zacks Research Has Bullish Estimate for Exelixis Q4 Earnings - MarketBeat
Peering Into Exelixis's Recent Short Interest - Benzinga
Exelixis's SWOT analysis: cancer drug maker's stock faces ip hurdle By Investing.com - Investing.com Canada
Exelixis's SWOT analysis: cancer drug maker's stock faces ip hurdle - Investing.com
Barclays PLC Sells 102,720 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Y Intercept Hong Kong Ltd Lowers Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis downgraded on balanced risk/reward after stock surge By Investing.com - Investing.com South Africa
Exelixis cut to neutral from buy by BofA - MSN
Bank of America Downgrades Exelixis (NASDAQ:EXEL) to Neutral - MarketBeat
Exelixis (EXEL) Cancer Drug Partnership Hits $110M Milestone as ADU-1805 Advances in Clinical Trials - StockTitan
Exelixis downgraded on balanced risk/reward after stock surge - Investing.com
Is Exelixis Positioned to Capitalize on Emerging Cancer Therapies? - Inkl
EXEL: Is Exelixis Positioned to Capitalize on Emerging Cancer Therapies? - StockNews.com
Public Employees Retirement System of Ohio Has $2.95 Million Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis, Inc. (NASDAQ:EXEL) Sees Significant Increase in Short Interest - MarketBeat
Retirement Systems of Alabama Grows Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
(EXEL) Investment Report - Stock Traders Daily
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report - Benzinga
Tri Ri Asset Management Corp Buys New Stake in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Kovitz Investment Group Partners LLC Takes Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis's SWOT analysis: cabozantinib drives growth amid ip challenges By Investing.com - Investing.com Canada
Exelixis's SWOT analysis: cabozantinib drives growth amid ip challenges - Investing.com
Unsupported price hikes added $815 million to US drug spending in 2023 - Marketscreener.com
State Street Corp Sells 1,157,988 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis, Inc. (NASDAQ:EXEL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why - MSN
Verition Fund Management LLC Invests $1.23 Million in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
2 Biotech Stocks to Buy Hand Over Fist in December - The Motley Fool
17,200 Shares in Exelixis, Inc. (NASDAQ:EXEL) Purchased by Point72 DIFC Ltd - MarketBeat
Cerity Partners LLC Acquires 15,777 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Fmr LLC Has $63.89 Million Holdings in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis (LTS:0IJO) Financial Strength : 8 (As of Sep. 2024) - GuruFocus.com
Systematic Financial Management LP Has $30.32 Million Stock Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
NFJ Investment Group LLC Makes New Investment in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
18,635 Shares in Exelixis, Inc. (NASDAQ:EXEL) Acquired by Paloma Partners Management Co - MarketBeat
Bank of Montreal Can Buys 35,496 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
BNP Paribas Financial Markets Sells 32,223 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis' (NASDAQ:EXEL) earnings growth rate lags the 29% CAGR delivered to shareholders - Yahoo Finance
Exelixis, Inc. (NASDAQ:EXEL) Stake Lessened by Jacobs Levy Equity Management Inc. - MarketBeat
Erste Asset Management GmbH Purchases New Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Edgestream Partners L.P. - MarketBeat
Which GCs Sold Stock In November? Quest, Exelixis, More - Law360
(EXEL) Technical Pivots with Risk Controls - Stock Traders Daily
Kidney Cancer Drugs Market Trends and Forecast 2024-2033 | Key - openPR
Exelixis EVP sells $2.2 million in stock By Investing.com - Investing.com Nigeria
Exelixis EVP sells $2.2 million in stock - Investing.com
Point72 Hong Kong Ltd Purchases Shares of 36,918 Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):